Phase 1 Ovarian Cancer Trial, Not Yet Recruiting (NCT07532148)

Phase 1 Ovarian Cancer Trial, Not Yet Recruiting NCT07532148 Sponsor: Chong Kun Dang Pharmaceutical Condition: Ovarian Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07532148 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ovarian Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 19 and 75 years old and have been diagnosed with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has a BRCA gene mutation and is classified as high-grade
Your body mass index (BMI) — a measure of body weight relative to height — is between 18.0 and 28.0

Who may not be able to join:

You have or have had a bowel or digestive condition (such as Crohn's disease or ulcers) that could affect how your body absorbs medicine, or that has required surgery
You have cancer that has spread to your brain or spinal cord, unless it has been treated and is currently considered stable
You have experienced severe side effects (graded 3 or higher) from a treatment called D215, such as serious anaemia, low white blood cell counts, low platelet counts, taste changes, cough, or other related reactions (confirm with trial site)
The trial doctor has determined, for any reason, that it would not be appropriate for you to take part in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 7 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jeong-Yeol Park, Ph.D, Asan Medical Center

Phone: 82-2-3010-3646

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07532148

Sponsor: Chong Kun Dang Pharmaceutical

Phase: Phase 1

Status: Not Yet Recruiting

Condition: Ovarian Cancer

Trial contact: 82-2-3010-3646

More information: https://clinicaltrials.gov/study/NCT07532148

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 19 and 75 years old and have been diagnosed with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has a BRCA gene mutation and is classified as high-grade
Your body mass index (BMI) — a measure of body weight relative to height — is between 18.0 and 28.0

Who may not be able to join:

You have or have had a bowel or digestive condition (such as Crohn's disease or ulcers) that could affect how your body absorbs medicine, or that has required surgery
You have cancer that has spread to your brain or spinal cord, unless it has been treated and is currently considered stable
You have experienced severe side effects (graded 3 or higher) from a treatment called D215, such as serious anaemia, low white blood cell counts, low platelet counts, taste changes, cough, or other related reactions (confirm with trial site)
The trial doctor has determined, for any reason, that it would not be appropriate for you to take part in this trial

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 7 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Not Yet Recruiting

Phase

Phase 1

Sponsor

Chong Kun Dang Pharmaceutical

Registry

ClinicalTrials.gov

Start date

1 June 2026

Est. completion

1 June 2027

Primary endpoints

AUCtau; Css,max

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov